






















Filed • Approved


 antibody  protein  small molecule

As of Dec. 31, 2018

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		<b>KRN321</b> <b>Darbepoetin Alfa</b> <b>Injection</b>	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
Oncology		<b>KW-0761</b> <b>Mogamulizumab</b> <b>Injection</b>	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	Approved in EU	In-House	POTELLIGENT®
Immunology/Allergy		<b>KHK4827</b> <b>Brodalumab</b> <b>Injection</b>	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in KR	Kirin-Amgen	
					Filed in SG		
					Filed in MY		
					Filed in HK		
Central Nervous System		<b>KW-6002</b> <b>Istradefylline</b> <b>Oral</b>	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	NDA in preparation in US	In-House	
Other		<b>©KRN23</b> <b>Burosumab</b> <b>Injection</b>	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Approved in CA	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
					Filed in IL		
					Filed in CH		
		<b>AMG531</b> <b>Romiplostim</b> <b>Injection</b>	Thrombopoietin Receptor Agonist	Aplastic Anemia	Filed in JP	Kirin-Amgen	




Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		<b>©RTA 402</b> <b>Bardoxolone Methyl</b> <b>Oral</b>	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	Phase III in JP	Licensed from Reata	
		<b>KHK7580</b> <b>Evocalcet</b> <b>Oral</b>	Calcium Receptor Agonist	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Phase III in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		<b>©KHK2375</b> <b>Entinostat</b> <b>Oral</b>	HDAC Inhibitor	Breast Cancer	Phase II in JP	Syndax	
		<b>KW-0761</b> <b>Mogamulizumab</b> <b>Injection</b>	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase II in US, EU and others	In-House	POTELLIGENT®
Immunology/Allergy		<b>©KHK4083</b> <b>Injection</b>	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase II in US, EU and others	In-House	POTELLIGENT® Human Antibody-Producing Technology
				Atopic Dermatitis	Phase II in JP, US, CA and EU		
		<b>KHK4563</b> <b>Benralizumab</b> <b>Injection</b>	Anti-IL-5 Receptor Humanized Antibody	Chronic Obstructive Pulmonary Disease (COPD)	Phase III in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune
				Eosinophilic Chronic Rhinosinusitis (ECRS)	Phase II in JP		
	<b>KHK4827</b> <b>Brodalumab</b> <b>Injection</b>	Anti-IL-17 Receptor A Fully Human Antibody	Axial Spondyloarthritis (axSpA)	Phase III in JP, KR and TW	Kirin-Amgen		
	<b>©ASKP1240</b> <b>Bleelumab</b> <b>Injection</b>	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in <i>de</i> <i>novo</i> kidney transplant recipients	Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas	
Central Nervous System		<b>KW-0761</b> <b>Mogamulizumab</b> <b>Injection</b>	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT®
		<b>©KW-6356</b> <b>Oral</b>	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	Phase II in JP	In-House	
Other		<b>©KRN23</b> <b>Burosumab</b> <b>Injection</b>	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients	Phase III in US, CA, EU, JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH) in pediatric patients	Phase III in US, CA, EU, AU, JP and KR		
				Tumor Induced Osteomalacia(TIO)/Epidermal Nevus Syndrome (ENS)	Phase II in US Phase II in JP and KR		
		<b>AMG531</b> <b>Romiplostim</b> <b>Injection</b>	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase II/III in KR	Kirin-Amgen	
Idiopathic (Immune) Thrombocytopenic Purpura	Phase III in CN						








 Updated since Sep. 30, 2018 (Area, Stage, Filed, Approved, etc.)


© New Molecular Entity

Ph I

 antibody
  protein
  small molecule

As of Dec. 31, 2018




Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		ⓈKHK2455 Oral	IDO1 Inhibitor	Solid Tumor	Phase I in US	In-House	Combination with KW-0761
		ⓈKHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I / II in US	In-House	POTELLIGENT® Combination with Nivolumab (Jointly Developed with Bristol-Myers Squibb)
Immunology/ Allergy		ⓈKHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase I in JP	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Autoimmune Disease	Phase I in JP	Kirin-Amgen	
Central Nervous System		ⓈKHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU Phase I in JP	Licensed from Immunas Pharma	
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	

 Updated since Sep. 30, 2018 (Area, Stage, Filed, Approved, etc.)

 New Molecular Entity

Updated since Sep. 30, 2018 (Area, Stage, Filed, Approved, etc.)

Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	Approved in EU	In-House	POTELLIGENT®
Other		ⓈKRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Approved in CA	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
					Filed in IL		
					Filed in CH		
					Filed in AE		
Immunology/ Allergy		ⓈKHK4083 Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	Phase II in JP, US, CA and EU	In-House	POTELLIGENT® Human Antibody-Producing Technology